Pulmonary Embolism Market Revenue to Attain USD 6.04 Bn by 2035
Published: 05 Mar 2026
Author: Precedence Research
Pulmonary Embolism Market Revenue and Trends 2026 to 2035
The global pulmonary embolism market revenue was valued at USD 2.70 billion in 2025 and is expected to attain around USD 6.04 billion by 2035, growing at a CAGR of 8.38% during forecast period.This market is experiencing unprecedented growth, driven by rising awareness of PE symptoms and the growing demand for personalized treatment options.
What are the Factors Contributing to the Growth of the Pulmonary Embolism Market?
The rising global incidence of venous thromboembolism (VTE) and deep vein thrombosis (DVT) is the major factor contributing to the overall growth of the pulmonary embolism market. Rapid and accurate diagnostic techniques, particularly CT pulmonary angiography (CTPA) and AI-driven algorithms, facilitate early detection. The market’s growth is also primarily supported by the surge in the surge in aging population and the rising shift towards DOACs and innovative therapeutic options.
Segment Insights
- By treatment type, the anticoagulants segment held the largest market share in 2025. They have emerged as a dominant treatment for both acute and long-term prevention of recurrent clots. The use of anticoagulants has significantly increased, owing to their minimal monitoring requirements, reduced bleeding risks, and predictable pharmacokinetics.
- By patient population, the patients with symptomatic pulmonary embolism segment accounted for the largest market share over the global market in 2025. These patients present with clear clinical symptoms, which propel the need for immediate diagnosis and therapeutic interventions.
- By drug route of administration, the intravenous segment registered its dominance by holding the largest share in 2025. It plays a vital role in the effective treatment of acute conditions due to its rapid onset of action. It is the most widely preferred route of administration in hospitals and emergency settings for high-risk or unstable patients.
- By drug type, the DOACs segment held a major revenue share in the market in 2025, owing to its high efficacy, superior safety profiles, and highly convenient long-term anticoagulation. In addition, the increasing incidence of cardiovascular disease and a growing aging population are anticipated to drive the segment’s growth.
- By end-use sector, the hospitals segment contributed the biggest market share in 2025. Hospitals are primary care hubs and have advanced infrastructure. Hospitals are equipped with innovative diagnostic technologies, strong teams of healthcare professionals, and wide access to life-saving therapies.
Regional Insights
North America dominated the global pulmonary embolism market by holding the highest market share in 2025. The region's dominance is characterized by the advanced healthcare infrastructure, high concentration of pharmaceutical companies, increasing elderly population, high healthcare spending, strong insurance coverage, increasing prevalence of cardiovascular diseases, increasing adoption of Direct Oral Anticoagulants (DOACs), and rapid advancements in diagnostic imaging.
On the other hand, Asia Pacific is projected to grow at a significant CAGR between 2026 and 2035. The region's growth is attributed to the significant investment in healthcare infrastructure, rising cases of cardiovascular diseases, a surge in the geriatric population, a supportive government framework, growing need for minimally invasive treatments, and widespread access to CT pulmonary angiography
Additionally, the rising adoption of sophisticated diagnostic tools, such as multi-detector CT (MDCT) and dual-energy CT (DECT), facilitates earlier and accurate detection of pulmonary embolism. Such factors are expected to drive the expansion of the market in the region during the forecast period.
pulmonary embolism Market Coverage
| Report Attribute | Key Statistics |
| Market Revenue in 2025 | USD 2.70 Billion |
| Market Revenue by 2035 | USD 6.04 Billion |
| CAGR from 2026 to 2035 | 8.38% |
| Quantitative Units | Revenue in USD million/billion, Volume in units |
| Largest Market | North America |
| Base Year | 2025 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa |
Recent Development
- In September 2025, Imperative Care recently announced positive efficacy and safety results from the pivotal Symphony-PE Trial (NCT06062329) evaluating the company’s Symphony Thrombectomy System in the treatment of acute pulmonary embolism (PE).
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7882
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344